MACBETH. Phase IV Study to evaluate the efficacy of aflibercept in subjects with neovascular Age-related Macular Degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy

19/03/2014

Study to evaluate the efficacy of aflibercept in subjects with neovascular Age-related Macular Degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy. Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of proangiogenic factors

If you are interested in taking part in a clinical trial, please call us at 935 950 155 and we will assess whether you are eligible. Further information on trials at research projects